A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

Summary

This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.

Timeline

Start

2022-01-06

Primary completion

2022-06-29

Completion

2022-11-18

Outcome

Outcome not reported

Stopped: “The company decision that terminated the further develop of the molecule and had notified FDA about the termination as well.”

Publications

• Huang Y, Lin Z, Guo X, Zhang F, Wang Y, Zhang Z, Chen J, Liu L, Zhu M, Li Y, Ni M, Zhen Z, Wu Z, Ling X, Zhou S, Xi Y, Yu Y, Liang W, Zhao J, Li L, He J, Sang L. Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials. Virol J. 2025 Nov 4;22(1):358. doi: 10.1186/s12985-025-02964-8.

Drugs

Indications